Tocilizumab-induced Granulomatous Vasculitis and Cutaneous Actinomycosis in a Patient with Rheumatoid Arthritis

Overview

Journal Postepy Dermatol Alergol

Publisher Termedia

Specialty Allergy & Immunology

Date 2022 Sep 12

PMID 36090738

Authors

Justyna Ziandarska

Magdalena Gorecka-Sokolowska

Rafal Czajkowski

Affiliations

Soon will be listed here.

Citing Articles

Rheumatoid arthritis complicated with cervical actinomycosis and ureteral obstruction: A case report and literature review.

Gan H, Ren X, Zou Y, Li L, Ding J, Peng L Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024; 49(5):818-824.

PMID: 39174896 PMC: 11341218. DOI: 10.11817/j.issn.1672-7347.2024.230501.

References

Arayssi T, Harfouche M, Darzi A, Al Emadi S, Alnaqbi K, Badsha H . Recommendations for the management of rheumatoid arthritis in the Eastern Mediterranean region: an adolopment of the 2015 American College of Rheumatology guidelines. Clin Rheumatol. 2018; 37(11):2947-2959. DOI: 10.1007/s10067-018-4245-5. View

Valour F, Senechal A, Dupieux C, Karsenty J, Lustig S, Breton P . Actinomycosis: etiology, clinical features, diagnosis, treatment, and management. Infect Drug Resist. 2014; 7:183-97. PMC: 4094581. DOI: 10.2147/IDR.S39601. View

Sakaue S, Sumitomo S, Kubo K, Fujio K, Yamamoto K . Tocilizumab-induced leucocytoclastic vasculitis in a patient with rheumatoid arthritis. Rheumatology (Oxford). 2014; 53(8):1529-30. DOI: 10.1093/rheumatology/keu008. View

Perez-de-Lis M, Retamozo S, Flores-Chavez A, Kostov B, Perez-Alvarez R, Brito-Zeron P . Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opin Drug Saf. 2017; 16(11):1255-1271. DOI: 10.1080/14740338.2017.1372421. View

Smolen J, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017; 76(6):960-977. DOI: 10.1136/annrheumdis-2016-210715. View

Abdulqader Y, Al-Ani M, Parperis K . Rheumatoid vasculitis: early presentation of rheumatoid arthritis. BMJ Case Rep. 2016; 2016. PMC: 5129099. DOI: 10.1136/bcr-2016-217557. View

Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T . Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008; 112(10):3959-64. DOI: 10.1182/blood-2008-05-155846. View

Cojocaru M, Cohocaru I, Chico B . New insight into the rheumatoid vasculitis. Rom J Intern Med. 2015; 53(2):128-32. DOI: 10.1515/rjim-2015-0017. View

Wong V, Turmezei T, Weston V . Actinomycosis. BMJ. 2011; 343:d6099. DOI: 10.1136/bmj.d6099. View

10.

Rodriguez-Pla A, Stone J . Vasculitis and systemic infections. Curr Opin Rheumatol. 2005; 18(1):39-47. DOI: 10.1097/01.bor.0000197999.58073.2e. View

11.

Genta M, Genta R, Gabay C . Systemic rheumatoid vasculitis: a review. Semin Arthritis Rheum. 2006; 36(2):88-98. DOI: 10.1016/j.semarthrit.2006.04.006. View

12.

Smith R, HEATON C . Actinomycosis presenting as Wegener's granulomatosis. JAMA. 1978; 240(3):247-8. View

13.

Belizna C, Hamidou M, Levesque H, Guillevin L, Shoenfeld Y . Infection and vasculitis. Rheumatology (Oxford). 2009; 48(5):475-82. PMC: 7107237. DOI: 10.1093/rheumatology/kep026. View

14.

Breton A, Lamblin G, Pariset C, Jullien D . Cutaneous actinomycosis associated with anti-TNF-alpha therapy: report of two cases. Dermatology. 2014; 228(2):112-4. DOI: 10.1159/000357522. View

15.

Koike R, Harigai M, Atsumi T, Amano K, Kawai S, Saito K . Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol. 2009; 19(4):351-7. PMC: 2720589. DOI: 10.1007/s10165-009-0197-6. View